India-headquartered contract research organization GVK Biosciences announced in a press release Monday that it has entered into an agreement with Endo Pharmaceuticals, part of Endo Health Solutions (NASDAQ:ENDP). GVK Bio will contribute to discovering a new clinical drug candidate under the deal, while Endo will help to develop and commercialize any resulting product.

The agreement, which first arose from GVK Bio's Early Discovery Assets concept, will look to uncover small molecules targeting a specific protein.

GVK Bio's CEO, Manni Kantipudi, was quoted in the press release as saying, "We are delighted to partner with Endo as it continues to build its discovery pipeline through external collaborations. This collaboration also confirms the value of our differentiated [Early Discovery Assets] concept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates."


This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.